** Shares of telehealth firm Hims and Hers HIMS.N, which offers compounded versions of weight-loss drugs, fall 20.4% to $52.8
** The U.S FDA says that a shortage of Novo Nordisk's NOVOb.CO weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved as per the agency's website
** The resolution could restrict how telehealth programs offer cheaper versions known as compounded drugs
** For HIMS and other compounders "this development starts the clock on having unfettered market access" to Novo's drugs, says brokerage Leerink Partners
** It will be critical to understand HIMS' legal pathway to selling personalized doses for semaglutide - since it is the primary way it can continue selling the drug, Leerink added
** US government regulations allow compounded versions of a branded drug to be sold to meet demand if the drug is in shortage
** Stock has risen nearly seven-fold in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.